skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Erdafitinib (Code C103273)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Erdafitinib

Definition: An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

Display Name: Erdafitinib

Label: Erdafitinib

NCI Thesaurus Code: C103273 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3641169  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-

External Source Codes: 
CAS Registry Number 1346242-81-6 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 741845
PDQ Open Trial Search ID 741845 (check for NCI PDQ open clinical trial info)
UMLS CUI C3641169

Other Properties:
     Name Value (qualifiers indented underneath)
code C103273
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom